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http://dx.doi.org/10.1016/j.jds.2013.0Abstract Background/purpose: Volatile anesthetics can produce toxic metabolites and lead
to postoperative renal or hepatic dysfunction. The aim of this retrospective study is to
compare the changes in renal and hepatic function after general anesthesia using two different
volatile anesthetics in prolonged surgery for oral malignancy.
Materials and methods: Patients anesthetized by desflurane or sevoflurane in prolonged sur-
gery (>10 hours) for oral malignancy during past 18 months were included. Common bio-
markers such as blood urea nitrogen, serum creatinine, serum aspartate aminotransferase
(AST), alanine aminotransferase (ALT) in postoperative week (POW) 1, 2, and 3 were the pri-
mary outcomes. The mean values and the incidence of abnormality of these biochemical
markers were also compared.
Results: In this study, 21 and 26 patients receiving desflurane and sevoflurane anesthesia,
respectively, were included. Blood urea nitrogen and creatinine levels were not significantly
different between the two groups. There was a 2.1-fold and a 3-fold increase in AST in
POW1 in the desflurane and sevoflurane groups, respectively. The incidence of marked eleva-
tion in AST (greater than 100 IU/L) was significantly higher in the sevoflurane group in POW1.
There was a 1.9-fold and a 3.2-fold increase in ALT in POW2 in the desflurane and sevoflurane
groups, respectively. The incidence of marked elevation in ALT was significantly higher in the
sevoflurane group in POW2.t of Anesthesiology, National Taiwan University Hospital, 4F, Chung-Shan South Road, Taipei 100,
inet.net (W.-H. Chan).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
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386 I.-H. Lin et alConclusion: Both desflurane and sevoflurane did not cause clinically significant nephrotoxicity
but produced a transient deterioration in liver function after prolonged anesthesia for oral
cancer surgery. Sevoflurane was associated with a more severe degree of liver damage than
desflurane in this study.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published
by Elsevier Taiwan LLC. All rights reserved.Introduction
Volatile halogenated anesthetics have remained the main-
stay of general anesthesia for decades, but these drugs are
notorious for their ability to cause varying degrees of he-
patic and renal dysfunction. Liver damage ranging from
mild increases in serum aminotransferases to massive he-
patic necrosis can occur after halothane anesthesia.1
Methoxyflurane anesthesia can lead to renal tubular
degeneration and microlithiasis, contributing to the
occurrence of postoperative renal failure.2 The generation
of toxic metabolitesdtrifluroacetyl acid (TFA) and inor-
ganic fluoride ionsdhas been implicated in the occurrence
of postoperative organ toxicities after general anesthesia.1
As a consequence, the two anesthetics have been less
frequently used in recent years.
Desflurane and sevoflurane both have a low fat solubility
and therefore provide a fast onset and recovery from
anesthesia.3 Desflurane is metabolized by hepatic cyto-
chrome P450 2E1, producing TFA, which is the same ensuing
toxic product after halothane metabolism. However, the
rate of metabolism in desflurane is far lower than that in
halothane (0.01% for desflurane vs. 20% for halothane).1
Consequently, desflurane is considered to be much less
toxic than halothane in theory. Nonetheless, sporadic case
reports of desflurane-induced hepatic injury are still found
in the literature.4 Sevoflurane appears to have negligible
effect on hepatic function because its metabolism does not
produce toxic TFA.1 Even so, sevoflurane-induced hepatic
failure has also been reported.5 Sevoflurane has also been
considered as nephrotoxic because it reacts with the base-
containing carbon dioxide absorber in the circuit of the
ventilator and produces compound A, which shows explic-
itly renal toxicity in rodents.1,3 In addition, the production
of inorganic fluoride after sevoflurane metabolism may
aggravate postoperative renal dyfunction.1,3 Although
desflurane and sevoflurane have been administered to
millions of people without apparent organ toxicity, most of
these patients are anesthetized only for a moderate dura-
tion. Based on the assumption that the severity of the organ
toxicity can increase with a longer duration of anesthesia,
the changes in hepatic and renal functions after prolonged
exposure to volatile anesthetics could become more
obvious and thus deserve to be examined. Several studies
were done to compare hepatic or renal effects using
different modes of delivering sevoflurane or compare sev-
oflurane with isoflurane in prolonged anesthesia.6e10 How-
ever, sevoflurane and desflurane have not been specifically
compared in this regard.
The surgery for oral malignancy usually takes a longer
time than most other types of surgery because of the needfor meticulous tumor resection and complex reconstructive
procedures done at the same time. Sevoflurane and des-
flurane are both suitable in anesthesia for such prolonged
surgery considering the character of fast recovery. We are
particularly interested in the effect of different anesthetics
on the changes in common clinical biomarkers of renal and
hepatic functions in order to define a more judicious se-
lection of anesthetic technique in prolonged anesthesia for
oral cancer surgery. Therefore, we conducted this retro-
spective cohort study to compare the changes in bio-
markers for hepatic and renal function after anesthesia
using either sevoflurane or desflurane in prolonged surgery
for oral malignancy within the setting of a university
medical center.
Materials and methods
Because of the retrospective nature of this study, it was
granted an exemption for obtaining written consent forms
by the institutional review board of our hospital. The charts
of patients receiving surgery for oral malignancy (including
tumor removal and reconstructive procedure) during the
past 18 months in a university medical center were included
for review. Only those with an operation time longer than
10 hours were included. Those with preexisting hepatic or
renal dysfunction, defined as an abnormal value in any one
of the preoperative biochemical markers [institutional
normal range: aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) less than 40 IU/L; blood urea ni-
trogen (BUN) and serum creatinine below 24 and 1.3 mg/dL,
respectively], were excluded from analysis. Patients who
were anesthetized by volatile anesthetics other than des-
flurane or sevoflurane were also excluded.
No premedication was given to any of the patients. The
induction regimen included intravenous propofol
(2e2.5 mg/kg), fentanyl (2e2.5 mg/kg), and cisatracurium
(1.5e2 mg/kg). Tracheal intubation was performed either
by direct laryngoscope or with the aid of fiberoptic guid-
ance as indicated. The choice of sevoflurane or desflurane
for maintenance of general anesthesia was up to the
anesthetist’s decision on the spot. Fresh gas flow was a
mixture of air and oxygen (both at a flow rate of 0.5 L/min,
total flow rate 1 L/min) as a routine during stable condi-
tions in our hospital. The concentrations of volatile anes-
thetics were maintained between 1 and 2 minimum alveolar
concentrations throughout the operation. Boluses of fen-
tanyl or cisatracurium were added for analgesia or muscle
relaxation as necessary. Transfusion and volume therapy
were started as per the decision of the anesthesiologist in
charge. Ephedrine or dopamine infusion was started to
maintain proper blood pressure if necessary.
Hepatorenal function after oral cancer surgery 387It is a routine matter to check the hematological and
biochemical profiles on a weekly basis postoperatively in
the majority of these patients. Therefore, we traced the
biomarkers for renal function (including BUN and serum
creatinine) and hepatic function (mainly serum AST and
ALT) in postoperative week (POW) 1, 2, and 3 while
reviewing the medical records. Albumin, total bilirubin,
major ions in serum, and hematological profiles were also
collected at the same time points. When a value of a
biomarker at any time point was missing and could not be
found in the charts, it was excluded from comparison at
that time point. Immediate postoperative data [1st post-
operative day (POD1)] were retrieved when possible. The
normal ranges of these biomarkers are as aforementioned.
The number of an elevation in AST or ALTwas defined as the
total case number with a value greater than 40 IU/L. A
marked elevation in AST/ALT level refers to a value greater
than 100 IU/L.
All data were expressed as mean  standard deviation or
percentage. The range or case number was shown in the
table in some variables. Categorical variables were
compared using the chi-square test or Fisher exact test
where appropriate. Continuous variables in the de-
mographic data were compared using the Student t test.
Changes in the biomarkers or hematological data were
compared to their respective preoperative values using a
paired t test. The difference was regarded as statistically
significant when the P value was less than 0.05.Table 1 Demographic data of the study populations.
Desflura
Age (y) 52  9
Sex (M/F) 18/3
Weight (kg) 62  11
Height (cm) 166  5
ASA class
I 0
II 4
III 17
Disease entity
Buccal cancer 14
Tongue cancer 3
Gingival cancer 3
Other 1
Duration of anesthesia (min) 852  1
Intraoperative fluid
Crystalloid (mL) 4945 
Colloid (mL) 1381 
Packed RBC (unit) 3  3 (0
Cases having blood transfusion 15 (71%
Intraoperative urine output (mL) 1477 
Intraoperative blood loss (mL) 770  3
Intraoperative fentanyl dose (mg) 569  1
Intraoperative inotropic use 6
ASA class: physical status classification suggested by the American So
Data are expressed as mean  standard deviation, ranges, or the num
All variables are not significantly different between the two groups.Results
A total of 69patients underwentprolongedgeneral anesthesia
in surgery for oralmalignancy inour hospital during thepast 18
months. Seven cases were excluded because isoflurane was
used for maintenance of anesthesia. Fifteen cases were
excluded because of abnormal preoperative liver function.
None of the patients were found to have abnormal renal
function preoperatively. Finally, 47 cases were included for
analysis. Twenty-one patients received desflurane for main-
tenance of anesthesia, whereas 26 patients received sevo-
flurane. Patients anesthetized with sevoflurane and
desfluranewere similarwith respect to age, sex, bodyweight,
body height, ASA (American Society of Anesthesiologists)
physical status, duration of anesthesia, intraoperative fluid
supplement or transfusion, urine output, estimated blood
loss, fentanyl dose, or inotropic use (Table 1).
With regard to the changes in biochemical markers of
renal function, serum BUN was slightly but significantly
increased 1 week after operation (POW1) compared to the
preoperative values only in the desflurane group. However,
none of the values exceeded the upper limit of the normal
range (24 mg/dL) in POW1. There was no significant change
in BUN levels at other time points in both groups. By
contrast, serum creatinine was significantly decreased on
POW1, POW2, and POW3 in both groups. There was no
significant difference in BUN or creatinine levels between
the two groups at all time points (Table 2).ne (N Z 21) Sevoflurane (N Z 26)
54  10
26/0
61  8
167  6
0
8
18
11
9
4
2
31 (675e1095) 775  123 (602e1071)
1324 4688  1408
631 1017  469
e10) 3  3 (0e10)
) 18 (69%)
544 1646  1066
47 (400e1500) 781  461 (400e2000)
37 (400e1000) 496  135 (200e750)
8
ciety of Anesthesiologists.
ber of cases.
388 I.-H. Lin et alSerum AST, ALT, total bilirubin, and albumin were used
to determine the changes in postoperative liver function
and are shown in Tables 3 and 4. The serum AST level
appeared unchanged on POD1, but was significantly
increased from preoperative values in POW1 and POW2
regardless of the choice of anesthetics. The increase in AST
was more remarkable in POW1: there was a 2.1-fold in-
crease in AST values in the desflurane group and a 3-fold
increase in the sevoflurane group. Although the fold of in-
crease was greater in the sevoflurane group, we were un-
able to show a significant difference in AST values between
the two groups. Approximately half of the patients had an
elevation in AST value in POW1 in both groups. However,
five patients in the sevoflurane group had a marked
elevation in AST at this time point, in contrast to none in
the desflurane group (P < 0.05). AST values returned to the
preoperative level in POW3 in both groups. The serum ALT
was significantly increased from preoperative values in
POW1 and POW2 in both groups. Unlike AST, the increases
in ALT peaked in POW2: there was a 1.9-fold increase in the
desflurane group and a 3.2-fold increase in the sevoflurane
group. The ALT value in POW2 was significantly higher in the
sevoflurane group than in the desflurane group (P < 0.05).
Moreover, both the incidences of an elevation (>40 IU/L) or
a marked elevation in ALT (>100 IU/L) in POW2 were
significantly higher in the sevoflurane group. The ALT values
returned to a level comparable to preoperative values in
POW3 in both groups. One patient in the sevoflurane group
experienced significant liver dysfunction in POW2 and 3
(AST and ALT values are 399 and 547 IU/L in POW2,
respectively). An abdominal sonogram revealed paren-
chymal liver disease, compatible with the clinical diagnosis
of acute hepatitis made by a hepatologist after excluding
the possibility of viral insult or other common drug-induced
hepatitis. The liver function returned to normal range
about 1 month after the operation. There was no such case
of persistent hepatic dysfunction in the desflurane group.
Serum total bilirubin was significantly increased on POD1,
but returned to the preoperative level in POW1, and then
decreased in POW2 and POW3 in both groups. SerumTable 2 Preoperative and postoperative levels of BUN and crea
Desflurane
Case number Value (mg/dL) No. of elevati
Blood urea nitrogen (BUN)
Pre Op 21 12.3  4.0 0
POW 1 21 15.5  4.9* 0
POW 2 19 14.1  5.0 0
POW 3 16 15.0  6.0 2
Creatinine (Cre)
Pre Op 21 0.96  0.17 0
POW 1 20 0.89  0.16* 0
POW 2 21 0.87  0.22* 0
POW 3 16 0.89  0.22* 1
Values are expressed as mean  standard deviation or number of cas
time points between the two groups. The cut-off value of elevation i
*P < 0.05 compared with corresponding preoperative value.
POW Z postoperative week; Pre Op Z preoperative.albumin was significantly decreased in POW1, POW2, and
POW3 compared to the preoperative values in both groups.
No significant difference in bilirubin or albumin level was
found at all time points between the two groups.
As for the hematological profile, hemoglobin level was
significantly decreased through POD1 to POW3 in both
groups. The white blood cell count was increased signifi-
cantly from POD1 to POW2, and then returned to preop-
erative levels in POW3. Platelet count decreased on POD1,
but increased above the preoperative values in POW2 and
POW3 in both groups. There was no significant difference
between the two groups with regard to the hemotological
profile at all time points (Table 5).
The changes in major ions in serum are shown in Table 6.
Serum sodium ion concentration decreased significantly in
POW1 and POW2 in the desflurane group and in POW2 and
POW3 in the sevoflurane group. The incidence of hypona-
tremia in POW2 was significantly higher in the sevoflurane
group. Serum potassium was significantly increased in
POW2 in both groups. Yet, the incidence of hyperkalemia
was similar. Serum chloride was significantly decreased in
POW2 in both groups, but only in the sevoflurane group in
POW3. No significant difference in ion concentrations was
observed at all time points between the two groups.Discussion
The hepatic and renal effects after prolonged anesthesia
using halogenated volatile anesthetics have been studied in
several previous reports.6e10 Nevertheless, the present
study has several unique points. First, the duration of
anesthesia was unanimously longer than 10 hours in all
cases, unlike that in some previous reports, which included
cases with a shorter duration of anesthesia.9 Second, pre-
vious studies only showed the data from several days to 1
week postoperatively.6,8e10 Our study showed data up to 3
weeks postoperatively. Lastly, we compared the difference
between desflurane and sevoflurane anesthesia in this study.
Such a difference has not been specifically addressed intinine of the study populations.
Sevoflurane
on Case number Value (mg/dL) No. of elevation
26 14.9  4.6 0
25 13.2  3.2 0
23 13.8  3.1 0
16 13.4  3.2 0
26 0.97  0.12 0
25 0.87  0.13* 0
24 0.82  0.14* 0
21 0.77  0.11* 0
es. No significant difference in BUN or Cre level was found at all
n BUN and Cre was 24 and 1.3 mg/dL, respectively.
Table 3 Preoperative and postoperative levels of aminotransferases of the study populations.
Desflurane Sevoflurane
Case
number
Value
(IU/L)
No. of
elevation
Marked
elevation
Case
number
Value
(IU/L)
No. of
elevation
Marked
elevation
Aspartate aminotransferase (AST)
Pre Op 21 20.5  6.3 0 0 26 19.9  5.4 0 0
POD 1 13 23.3  8.9 2 0 6 31.7  13.0 1 0
POW 1 21 44.1  23.6* 9 0 20 60.2  51.4* 10 5y
POW 2 19 29.2  9.2* 3 0 23 36.7  18.8* 8 0
POW 3 16 24.3  9.9 1 0 14 40.9  58.4 2 1
Alanine aminotransferase (ALT)
Pre Op 21 22.3  9.7 0 0 26 23.0  8.7 0 0
POW 1 19 38.4  20.3* 6 1 19 58.5  67.2* 9 2
POW 2 18 41.3  20.4* 5 0 23 74.7  58.1*y 16y 8y
POW 3 14 24.8  11.2 2 0 17 61.0  127.8 5 1
Values are expressed as mean  standard deviation or number of cases. No. of elevation in AST/ALT level was defined as the total case
number having a value greater than 40 IU/L at the time point. Marked elevation in AST/ALT level referred to a value greater than
100 IU/L.
*P < 0.05 compared with the corresponding preoperative value.
yP < 0.05 compared with the desflurane group.
POD Z postoperative day; POW Z postoperative week; Pre Op Z preoperative.
Hepatorenal function after oral cancer surgery 389those who underwent prolonged anesthesia in the past. The
primary results of this study were as follows: (1) prolonged
sevoflurane did not produce clinically significant renal
injury; (2) transient increases in serum aminotransferases
were found after prolonged anesthesia using either sevo-
flurane or desflurane; such an increase peaked in the 1st to
2nd week and mitigated in the 3rd week postoperatively; (3)
postoperative increases in aminotransferases appeared to
be higher in those who received sevoflurane than those who
received desflurane; the incidence of marked elevation inTable 4 Preoperative and postoperative levels of bilirubin
and albumin of the study populations.
Desflurane Sevoflurane
Case
number
Value
(mg/dL)
Case
number
Value
(mg/dL)
Total bilirubin
Pre Op 21 0.65  0.21 26 0.74  0.28
POD 1 12 1.41  0.68* 6 1.51  0.71*
POW 1 12 0.57  0.16 15 0.66  0.23
POW 2 19 0.46  0.14* 18 0.48  0.19*
POW 3 14 0.39  0.12* 14 0.47  0.18*
Albumin
Pre Op 19 4.6  0.4 26 4.6  0.2
POW 1 18 3.2  0.5* 22 3.3  0.5*
POW 2 17 4.0  0.3* 20 4.0  0.3*
POW 3 14 4.1  0.4* 16 4.1  0.3*
Values are expressed as mean  standard deviation or number
of cases. No significant difference in bilirubin or albumin level
was found at all time points between the two groups.
*P < 0.05 compared with corresponding preoperative value.
POD Z postoperative day; POW Z postoperative week; Pre
Op Z preoperative.aminotrasferases was also higher in the sevoflurane group
than in the desflurane group.
As aforementioned, inorganic fluoride ions and com-
pound A can cause renal injury after sevoflurane anes-
thesia, particularly in laboratory animals. However,
sevoflurane has been administered to millions of patients
without any confirmed report of anesthetic-induced in-
crease in BUN or creatinine postoperatively up to now.1 The
present study also supports the idea that prolonged sevo-
flurane anesthesia does no harm to the kidney. The lack of
sevoflurane-related renal damage can be explained in
several ways. Intrarenal fluoride concentration could be
lower despite the higher plasma concentrations after sev-
oflurane anesthesia, rendering it less nephrotoxic.11 In
addition, it is generally believed that a process involving
bioactivation by renal b-lyase plays a pivotal role in com-
pound A-induced renal cell damage in rats.1 The metabolic
activity of renal b-lyase is 7e26 times lower in humans than
in rats.12 Taken together, these facts could explain, at least
partly, the lack of sevoflurane-related renal toxicity in
humans.
The proposed mechanisms of volatile anesthetic-
induced hepatic dysfunction include: (1) reduced hepatic
blood flow during anesthesia,13 (2) increased cytosolic
calcium ion concentration in hepatocytes,14 and (3) gen-
eration of toxic metabolite.1 TFA has been identified as the
hepatotoxic metabolite of desflurane. One of the gluta-
thione S-conjugates of compound A was found to increase
liver enzyme and produced centrilobular necrosis in rat
liver,15 and could possibly account for the hepatic
dysfunction after sevoflurane anesthesia. In this study, we
found that sevoflurane led to more severe hepatic damage
compared with desflurane. In another study, desflurane was
also found to preserve liver function better than sevo-
flurane after a moderate duration of anesthesia.13 The
reason for such a phenomenon is not clear because no
mechanistic exploration was done in both studies. It was
Table 5 Preoperative and postoperative hematologic profile of the study populations.
Desflurane Sevoflurane
Case number Value (g/dL) Case number Value (g/dL)
Hemoglobin
Pre Op 21 14.1  2.3 26 13.6  1.6
POD 1 16 9.8  1.7* 19 10.8  1.8*
POW 1 20 10.4  1.3* 26 10.6  1.5*
POW 2 21 10.6  1.0* 26 10.9  1.1*
POW 3 17 10.8  0.9* 18 11.0  0.8*
Desflurane Sevoflurane
Case number Cell count (103/mL) Case number Cell count (103/mL)
White blood cells
Pre Op 21 7.83  1.84 26 7.64  2.38
POD 1 12 11.81  3.50* 11 11.38  2.63*
POW 1 20 10.42  4.23* 26 10.58  3.12*
POW 2 21 9.65  3.58* 26 8.55  2.08*
POW 3 16 7.11  2.23 17 6.66  1.79
Platelets
Pre Op 21 265  82 26 259  80
POD 1 11 173  57* 10 192  42*
POW 1 20 307  108* 26 269  65
POW 2 21 569  176* 26 498  125*
POW 3 14 422  224* 18 360  113*
Values are expressed as mean  standard deviation or number of cases. No significant difference in hematologic profile was found at all
time points between the two groups.
*P < 0.05 compared with corresponding preoperative value.
POD Z postoperative day; POW Z postoperative week; Pre Op Z preoperative.
Table 6 Preoperative and postoperative levels of plasma electrolytes of the study populations.
Desflurane Sevoflurane
Case number Value (mmol/L) Abnormal level Case number Value (mmol/L) Abnormal level
Sodium
Pre Op 21 139  2 0 26 137  3 5
POW 1 21 135  3* 7 25 135  4 10
POW 2 21 136  3* 4 26 135  3* 14y
POW 3 17 138  3 1 18 136  3* 5
Potassium
Pre Op 21 4.32  0.43 0 26 4.36  0.47 0
POW 1 21 4.34  0.45 0 24 4.32  0.31 0
POW 2 21 4.87  0.53* 2 25 4.64  0.45* 1
POW 3 16 4.58  0.41 0 17 4.52  0.35 0
Chloride
Pre Op 21 103  3 0 26 102  4 4
POW 1 11 101  2 1 12 100  3 3
POW 2 20 100  3* 5 24 99  3* 6
POW 3 16 101  3 1 18 100  2* 2
Values are expressed as mean  standard deviation or number of cases. The normal range of sodium was defined as 135e148 mmol/L,
potassium as 3.5e5.3 mmol/L, and chloride as 98e108 mmol/L. No significant difference in ion concentrations was found at all time
points between the two groups.
*P < 0.05 compared with corresponding preoperative value/
yP < 0.05 compared with desflurane group.
POW Z postoperative week; Pre Op Z preoperative.
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Hepatorenal function after oral cancer surgery 391suggested that the differential ability of the two anes-
thetics to decrease hepatic blood flow might explain their
effects on postoperative liver function.13 Another possible
reason is that the S-conjugates of compound A could exert a
stronger toxic effect than TFA. In any case, desflurane
seems to be a preferable choice in patients receiving
anesthesia for prolonged oral cancer surgery.
Although we showed several differences in the changes
in hepatic function after prolonged general anesthesia for
oral cancer surgery using two different anesthetics, some
factors other than the choice of volatile anesthetics could
still affect the extent of change in liver function. Concur-
rent medications, especially antibiotics, could also
contribute to the postoperative changes in liver function.
However, all antibiotic medications were prescribed
following the same protocol in both groups. We also
reviewed the charts to rule out the concurrent use of
potentially hepatotoxic drugs apart from antibiotics. The
differences in liver function between the two groups did
not seem to be caused by other concurrent medications.
However, elevations in blood AST and ALT levels in some
patients could be due to posttransfusion hepatitis. We did
not routinely check the hepatitis profile in every patient
before or after the operation. Therefore, we could not
completely rule out the possibility of posttransfusion hep-
atitis in all patients. Nonetheless, several reasons promp-
ted us not to consider posttransfusion hepatitis as the
major factor to cause the difference in postoperative he-
patic injury between the two groups. The incidence of
elevated aminotransferases in this study was too high
compared with the reported incidence of posttransfusion
hepatitis in Taiwan, particularly in the sevoflurane group.16
The mean peak ALT value in posttransfusion hepatitis
(>300 IU/L) was significantly higher than what we found in
this study.16 The average incubation period for post-
transfusion hepatitis was reported to be as long as 46 days.
There was a significant incidence (60%) of turning into
chronic hepatitis in the case of posttransfusion hepatitis.16
In contrast, liver injury occurred only 1 or 2 weeks after the
operation and was usually self-limited and resolved within 1
month in our study. As a matter of fact, the patient with
the most prolonged deterioration in liver function in this
study did not receive any transfusion during the operation,
and serology tests excluded any sign of insult from viral
origin (after consulting a hepatologist). In addition, the
amount and the case number of transfusion were not
different between the two groups. We could not reasonably
infer that the difference in postoperative liver function was
a result of transfusion. Collectively, we considered that the
clinical manifestation in this study could not properly fit
posttransfusion hepatitis, and transfusion alone was not
sufficient to explain the difference between the two
groups. Lastly, this is a retrospective cohort study with a
relatively limited case number. Some missing data during
the follow-up period make the comparison more difficult. A
better-designed prospective, randomized study with
adequate case number is expected to confirm the findings
of this study.
In conclusion, this study reassured the lack of clinically
relevant sevoflurane-related nephrotoxicity after pro-
longed anesthesia for oral cancer surgery. A transientdeterioration in liver function was found after prolonged
anesthesia for oral cancer surgery using desflurane or sev-
oflurane. However, sevoflurane might produce a more se-
vere degree of liver damage than desflurane after
prolonged anesthesia. Such a result alerts healthcare
personnel that the choice of the anesthetic agent may have
an impact on postoperative hepatic function and warrants
the need for a more comprehensive study on the hepatic
effects of different anesthetic techniques in prolonged oral
cancer surgery.References
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